Related references
Note: Only part of the references are listed.A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer
Do-Youn Oh et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Phase II trial of S-1 in combination with gemcitabine for chemo-na⟨ve patients with locally advanced or metastatic pancreatic cancer
Gyeong-Won Lee et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
S-1: a promising new oral fluoropyrimidine derivative
Muhammad Wasif Saif et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
S-1 and Gemcitabine as an Outpatient-based Regimen in Patients with Advanced or Metastatic Pancreatic Cancer
Min Kyoung Kim et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2009)
Development History and Concept of an Oral Anticancer Agent S-1 (TS-1((R))): Its Clinical Usefulness and Future Vistas
Tetsuhiko Shirasaka
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
David Cunningham et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A late phase II study of S-1 for metastatic pancreatic cancer
Takuji Okusaka et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
An early phase II study of S-1 in patients with metastatic pancreatic cancer
H Ueno et al.
ONCOLOGY (2005)
Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297
JD Berlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
